Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy
Asia-Pacific Journal of Clinical Oncology · 2026
DOI: 10.1111/ajco.14205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von Junipearl Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Western Sydney University, Campbelltown, NSW, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC). We reviewed the real‐world outcomes of patients who received pembro‐chemo versus pembro only.
Methods
This Australian‐based retrospective cohort study used data from patients with advanced NSCLC PD‐L1 ≥ 50%, diagnosed between January 2016 and July 2021 and had received first‐line pembro‐chemo or pembro only. Patients with an EGFR/ALK/ROS1 sensitizing mutation were excluded. Cox proportional‐hazards model and Kaplan–Meier methods were used to estimate OS and progression‐free survival (PFS).
Results
Of 111 eligible patients, 25 received pembro‐chemo and 86 received pembro only. After a median follow‐up of 15.7 months, median (95% CI) OS was not reached in the pembro‐chemo group versus 15.6 (9.5–21.7) months in the pembro‐only group (HR 0.57, 95% CI 0.28–1.16, p = 0.12). Median PFS was 12.4 (6.5–18.3) versus 9.5 (6.3–12.6) months in pembro‐chemo versus pembro‐only groups, respectively (HR 0.62, 95% CI 0.32–1.18, p = 0.18). Objective response rate (ORR) was higher in the pembro‐chemo group (60% vs. 30.3%). There were more hospitalizations in the pembro‐chemo group versus pembro‐only group, 28% versus 18.6%, but immune‐related adverse events were similar (32% vs. 32.6%).
Conclusion
In patients with PD‐L1 ≥ 50% advanced NSCLC, addition of chemo to first‐line pembro yielded a higher ORR but no additional benefit in PFS or OS, supporting a shared‐decision approach. However, higher rates of hospitalizations seen in the pembro‐chemo group should warrant caution in use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
- Liverpool Cancer Therapy Hospital, Liverpool Hospital, Liverpool, NSW, Australia.
- Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW, Australia.
- NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, Australia.
Zitieren
APA
Cheng, J., McKay, C., Bray, V., Yip, P. Y., Tognela, A., & Kok, P. S. (2026). Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14205
Vancouver
Cheng J, McKay C, Bray V, Yip PY, Tognela A, Kok PS. Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.14205
BibTeX
@article{Cheng2026,
author = {Cheng, Junipearl and McKay, Charlotte and Bray, Victoria and Yip, Po Yee and Tognela, Annette and Kok, Peey Sei},
title = {Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.14205}
}
EUVIMED